748 related articles for article (PubMed ID: 36369487)
1. Evolving therapeutic landscape of advanced hepatocellular carcinoma.
Yang C; Zhang H; Zhang L; Zhu AX; Bernards R; Qin W; Wang C
Nat Rev Gastroenterol Hepatol; 2023 Apr; 20(4):203-222. PubMed ID: 36369487
[TBL] [Abstract][Full Text] [Related]
2. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma: Advances in systemic therapies.
Wu TK; Hui RW; Mak LY; Fung J; Seto WK; Yuen MF
F1000Res; 2024; 13():104. PubMed ID: 38766497
[TBL] [Abstract][Full Text] [Related]
4. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.
Kudo M
World J Gastroenterol; 2019 Feb; 25(7):789-807. PubMed ID: 30809080
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapies in hepatocellular carcinoma: A revolution?
Fortuny M; Sanduzzi-Zamparelli M; Reig M
United European Gastroenterol J; 2024 Mar; 12(2):252-260. PubMed ID: 38267015
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.
Liu TH; Shen YC; Cheng AL
J Formos Med Assoc; 2022 Aug; 121(8):1371-1383. PubMed ID: 35400583
[TBL] [Abstract][Full Text] [Related]
7. Updates on Systemic Therapy for Hepatocellular Carcinoma.
Ntellas P; Chau I
Am Soc Clin Oncol Educ Book; 2024 Jan; 44():e430028. PubMed ID: 38175973
[TBL] [Abstract][Full Text] [Related]
8. [Advances in targeted and immune therapies for hepatocellular carcinoma].
Nan YM; Miao TG
Zhonghua Gan Zang Bing Za Zhi; 2022 Sep; 30(9):905-911. PubMed ID: 36299181
[TBL] [Abstract][Full Text] [Related]
9. Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials.
An J; Han S; Kim HI; Shim JH
Hepatol Commun; 2022 Oct; 6(10):2886-2900. PubMed ID: 35785525
[TBL] [Abstract][Full Text] [Related]
10. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
[TBL] [Abstract][Full Text] [Related]
11. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.
Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR
Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
[TBL] [Abstract][Full Text] [Related]
13. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
Tella SH; Kommalapati A; Mahipal A; Jin Z
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
[TBL] [Abstract][Full Text] [Related]
15. [Status Quo and Development of Immunotherapy for Hepatocellular Carcinoma].
Wang T; Wang WT
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):692-698. PubMed ID: 37248607
[TBL] [Abstract][Full Text] [Related]
16. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
Wong KM; King GG; Harris WP
Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
18. Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations.
Storandt MH; Mahipal A; Tella SH; Kommalapati A; Jin Z
J Hepatocell Carcinoma; 2022; 9():1187-1200. PubMed ID: 36471742
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma.
Shen W; Chen Y; Lei P; Sheldon M; Sun Y; Yao F; Ma L
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291797
[TBL] [Abstract][Full Text] [Related]
20. Paradigm shift in the treatment options of hepatocellular carcinoma.
Su TH; Hsu SJ; Kao JH
Liver Int; 2022 Aug; 42(9):2067-2079. PubMed ID: 34515412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]